The insider trading activity was very torpid in the past two holiday-shortened trading weeks, but several companies still witnessed heavy insider selling. As a general rule, insider selling points to grim prospects in the upcoming future, but this type of activity should be closely examined in order to avoid the misinterpretation of the information it carries. The likelihood of wrongly interpreting insider selling is extremely high, as insiders can sell shares for numerous reasons that might not be related to their companies’ current developments or future prospects. Despite that, certain insider sales may still accurately predict that some companies do not have such a bright future as most market participants might have anticipated. At the end of the day, corporate insiders are the ones who have more up-to-date and in-depth knowledge about their companies’ current challenges and future prospects. For that reason, this article will discuss the recent insider selling reported at three companies and examine the recent performance of the companies in question.
Prior to discussing the insider trading activity, let’s make you familiar with what Insider Monkey does. At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read the details here). Since the official launch of our small-cap strategy in August 2012, it has performed just as predicted, returning over 102% and beating the market by more than 53 percentage points. We believe the data is clear: investors will be better off by focusing on small-cap stocks utilizing hedge fund expertise (while avoiding their high fees at the same time) rather than large-cap stocks.
Celgene Corporation (NASDAQ:CELG) is among the companies that witnessed heavy insider selling in the past two weeks. Director Ernest Mario unloaded 40,000 shares last Monday at prices that ranged from $118.56-to-$120.16 per share, cutting his overall holding to 82,449 shares. Director Michael D. Casey reported selling 20,000 shares on December 23 at a weighted average price of $122.11, all of which were held through a family trust fund. After the recent sale, the trust fund holds an ownership stake of 125,485 shares. The shares of this integrated global biopharmaceutical company are up slightly more than 5% in 2015 and most financial hubs have great expectations about the company’s future performance. In early November, UBS reiterated its ‘Buy’ rating on Celgene Corporation (NASDAQ:CELG), but lowered its price target to $145 from $156. Similarly, Cantor Fitzgerald reiterated its ‘Buy’ rating on the stock in mid-December, citing strong fundamentals and convincing pipeline. The company’s revenue for the nine-month period ended September 30 totaled $6.69 billion, up by $1.11 billion year-on-year. Celgene’s oral immunomodulatory drug REVLIMID, POMALYST/IMNOVID, and anti-inflammatory drug OTEZLA stand behind the company’s top-line growth. Meanwhile, analysts anticipate full-year earnings per share growth of nearly 19% next year to $5.71 per share. Samuel Isaly’s Orbimed Advisors cut its stake in Celgene Corporation (NASDAQ:CELG) by 7% during the third quarter to 3.59 million shares.